TIMM9

Across TCGA pan-cancer cohorts, TIMM9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TIMM9 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TIMM9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TIMM9 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where TIMM9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.649	0.372	.006	27	view →
CCRCC	DFS	Quartile	All	0.625	1.000	.001	21	view →
GBM	DFS	Tertile	All	0.224	0.427	.027	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
HNSC	DFS	Tertile	II,III,IV	0.703	0.877	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TIMM9–PDAC (OS)

Open the PDAC breakdown →